Final OS analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) presented at the 2026 ESMO

Summary

Median OS was extended by 8.5 months compared to platinum-based double chemotherapy (25. 9 vs. 17. 4 months), with a 31% reduction in the risk of death (HR 0. 69; 95% CI 0. 540. 89; unilateral P = 0. 0021).